The information below is intended for healthcare providers
pharma& is dedicated to preserving the availability and fostering the further development of essential medicines worldwide to leave no patient behind, breathing new life into proven medicines.
Global Pegasys® supply availability update
Pegasys® (peginterferon alfa-2a) product supply is currently impacted globally, with a number of countries with limited or no availability. Access to Pegasys® supply will continue to become more limited until product replenishment. Supply replenishment dates are country-dependent. Unfortunately, the Pegasys® supply situation is worldwide and not specific to an individual country or region.
At pharma&, we recognize that the worldwide Pegasys® availability situation creates incredible strain for patients and their healthcare team, and pharma& wants to assure you that we understand the importance of treatments like Pegasys® and are dedicated to investing in the medicine to ensure a long-term stable supply.
Managing the Global Pegasys® supply
pharma& acquired the global rights to Pegasys® in 2021 with the aim of ensuring continuity of care for eligible patients after the previous manufacturer announced it would cease commercialization of Pegasys®. Due to recent market changes Pegasys® demand has increased significantly and as a result, the final product batch produced by the previous manufacturer will not last for the intended period of approximately 10 years, and pharma& has looked to expedite our manufacturing plan.
Our commitment to long-term Pegasys® supply
pharma& is committed to investing into Pegasys®, as well as the ongoing development and future certification of our bio-manufacturing capabilities at our wholly owned manufacturing plant in Austria, Loba biotech GmbH. While Pegasys® is a complex biological product to manufacture, this significant investment to enhance production capabilities reflects pharma&’s dedication to securing and enduring a stable supply chain long-term for eligible patients.
Questions and Contact Information
We thank you for your understanding and patience during this period, pharma& will continue to assess the availability of Pegasys®, and we remain dedicated to ensuring your patients’ long-term access to this medicine.
We are working closely with local regulatory authorities during this period to ensure we can provide transparent and open communication updates when available.
For further questions or details of the supply replenishment timeline in your country, please contact the pharma& Medical Information team.
- For medical information inquiries outside of the U.S., contact pharma& at medinfo@pharmaand.com.
- For medical information inquiries within the U.S., contact pharma& at medinfo.us@pharmaand.com.
In addition, please contact the following in the case of any suspected adverse reaction or product complaint.
- Healthcare professionals should report any suspected adverse reactions via their national reporting systems.
- In the US, you may report adverse events to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
- Alternatively, to report an adverse event or reaction, contact pharma& at pv@pharmaand.com.
- To report a product complaint, contact pharma& at complaints@pharmaand.com.
Safety Information
EPAR (last updated 04/09/2024)
SmPC – Product Information (last updated 05/08/2024)
For non-EU countries please refer to your local health authority
For U.S.A. USPI (last updated 02/2024)
For Canada – As previously supplied by Hoffmann-La Roche Limited, the pre-filled syringe is the only Pegasys® format available from pharmaand GmbH and Accelera Pharma Canada Inc.
Pour le Canada – La seringue préremplie Pegasys®, fournie auparavant par Hoffmann-La Roche Limited, est l’unique présentation disponible auprès de pharmaand GmbH et Accelera Pharma Canada Inc.